- Home
- SLXN
SLXN
BIOMOTION SCIENCES
as 04-01-2025 3:42pm EST
Stocks
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
| Founded: | 2008 | Country: | Israel |
| Employees: | N/A | City: | RAMAT GAN |
| Market Cap: | 4.3M | IPO Year: | N/A |
| Target Price: | $5.00 | AVG Volume (30 days): | 5.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -81.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.21 - $13.56 | Next Earning Date: | 05-21-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BIOMOTION SCIENCES News
SLXN Breaking Stock News: Dive into SLXN Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
GlobeNewswire
12 days ago
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
GlobeNewswire
15 days ago
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Business Wire
16 days ago
PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment
GlobeNewswire
a month ago
Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
Business Wire
a month ago
PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational
GlobeNewswire
a month ago
Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
GlobeNewswire
2 months ago
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Compare SLXN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLXN BIOMOTION SCIENCES - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.